Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

of young adults, with onset typically before age 40.

Common symptoms of the disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Over the course of their disease, up to 75 percent of patients with Crohn's will undergo surgery for complications or disease resistant to treatment.

"Crohn's disease is a life-long condition with no known cure. One of the goals of treatment is to induce and maintain remission, which can help patients with their chronic symptoms," said Remo Panaccione, M.D., Associate Professor, and Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and study author. "In this study, many patients taking HUMIRA during a lengthened treatment period showed clinical response and remission, which translates into improvement of disease symptoms."

About the Open-Label Extension Study

The two analyses from the ongoing extension study focused on the efficacy of HUMIRA in maintaining remission and achieving response during long-term follow-up periods. A diverse group of patients with moderate to severe Crohn's disease were represented, including those who were naive to anti-TNF agents or who had previously lost response or were unable to tolerate infliximab.

At the end of CHARM and GAIN, patients were eligible for enrollment in the OLE study (N=467 enrolled). Patients enrolled from the blinded, randomized arms from CHARM and GAIN received HUMIRA 40 mg every other week (EOW) and patients enrolled from the open-label arm of CHARM received their previous open-label regimens [40 mg EOW or every week (EW)]. Patients in the OLE study could be switched to EW dosage for flare or non-response. The results from both HUMIRA doses were pooled for the analyses.

About the CHARM Trial

The CHARM (Crohn's trial of the fully Human antibody Adalimumab for Remission Maintenance) study enrolled 854 patients, both anti-TNF naive and anti-TNF experienced, wi
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today ... Friday, June 17, 2011. At the meeting, shareholders approved the ... to increase the total number of authorized shares and authorized ... Therapeutics, Inc. Headquartered in Seattle, CTI ...
... 17, 2011 Unilife Corporation ("Unilife" or the ... Kathleen Merrigan, the Deputy Secretary of the U.S. Department of ... local business leaders at its facility in York, Pennsylvania. ... (WHBC) under the direction of President Obama. The Winning ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Unilife Hosts White House Business Council Meeting 2Unilife Hosts White House Business Council Meeting 3
(Date:4/18/2014)... A new article published online in The ... to religious music is associated with a decrease in ... and sense of control over their lives. In particular, ... in anxiety about death and an increase in sense ... and whites, women and men, and individuals of both ...
(Date:4/18/2014)... 2014) Benaroya Research Institute at Virginia Mason (BRI) ... particular molecule in metastatic breast cancer reduces both the ... metastases. BRI scientists have found in models of the ... 60 - 80 percent and can keep the tumor ... million five-year grant comes from the National Cancer Institute ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Diego School of Medicine report that older women, plucky ... loss are more likely to be compassionate toward strangers ... in this month,s issue of the International Journal ... associated with better health and well-being as we age, ... the outcomes of individuals whose deficits in compassion put ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... YORK, Feb. 12 Medicare now pays for treatments ... change that and apply a cost-effectiveness standard set by ... Effectiveness Research.The Federal Council is modeled after a U.K. ... This British board approves or rejects treatments using ...
... damage, and study says it,s likely all that sugar , , THURSDAY, ... cans of soda pop daily are almost two times more likely ... to a U.S. study. , But there,s no increased risk for ... drink diet soda. , The researchers analyzed data from 9,358 adults ...
... The Final Inch and Slumdog Millionaire show the challenges ... Astute Oscar-watchers are getting a short ... nominated films that together show the status of this ... four countries where the virus has not been stopped. ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 19, 2009, and will host a conference call to discuss these ... , , , Date: Thursday, February ... Conference call access:, Internet: www.istavision.com, ...
... got radiation treatment for Hodgkin,s disease are almost 40 times ... findings from five institutions, including the University of Florida. ... researchers report. These women are also likely to develop cancer ... get rid of the cancer. Our second priority is to ...
... Pamper Tired TootsiesBETHESDA, Md., Feb. 12 Valentine,s Day marks ... men and women. While the old adage "a way to ... true, another body part is gaining affection from both sexes ... (APMA) survey revealed 84 percent of women are embarrassed about ...
Cached Medicine News:Health News:2 or More Sodas a Day Boost Women's Kidney Risks 2Health News:Oscar Nominated Films Raise Polio Awareness 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 2Health News:Pediatric Hodgkin's disease survivors face increased breast cancer risk 3Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 2Health News:American Podiatric Medical Association Helps Americans 'Love' Their Feet This Valentine's Day 3
... Excaliburplus PC, 100V, 50Hz/60Hz is the most ... V PTP in spray Coag. It is the ... power settings from the surgical field with a ... Output Voltage in CUT maintains minimum necessary voltage ...
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Medicine Products: